Benzinga | Sep 22, 2021 07:17AM EDT

Addex Therapeutics, CMTA Join Forces To Develop Potential Treatment For Rare Neurological Disorder

* The Charcot--Marie--Tooth Association (CMTA), a philanthropic funder of CMT research worldwide, and Addex Therapeutics Ltd (NASDAQ:ADXN) have collaborated to investigate a potential therapy for CMT type 1A (CMT1A).

* Charcot-Marie-Tooth disease type 1A (CMT1A) is an inherited neurological disorder that affects the peripheral nerves.

* People with this disease experience weakness and wasting (atrophy) of the muscles of the lower legs beginning in adolescence; later, they can also have hand weakness and sensory loss.

* The primary goal of the collaboration is to evaluate the benefit of Addex's positive allosteric modulators (PAM) targeting the gamma-aminobutyric acid subtype B (GABAB) receptor in rodent models.

* The GABAB receptor has previously been shown to be instrumental in controlling the Peripheral Myelin Protein-22 (PMP22) overexpression in a rat model of CMT1A.

* Elevated PMP22 is closely associated with the disabling peripheral neuropathy that accompanies CMT1A.

* Read Next: Addex Therapeutics Starts Mid-Stage Study For Dipraglurant In Parkinson's Associated Dyskinesia

* Price Action: ADXN shares are up 0.57% at $9.70 during the premarket session on the last check Wednesday.